- Home
- EOD vs CERS Comparison
EOD vs CERS Comparison
Compare EOD & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOD
- CERS
- Stock Information
- Founded
- EOD 2007
- CERS 1991
- Country
- EOD United States
- CERS United States
- Employees
- EOD N/A
- CERS N/A
- Industry
- EOD Investment Managers
- CERS EDP Services
- Sector
- EOD Finance
- CERS Technology
- Exchange
- EOD Nasdaq
- CERS Nasdaq
- Market Cap
- EOD 245.0M
- CERS 255.0M
- IPO Year
- EOD N/A
- CERS 1997
- Fundamental
- Price
- EOD $5.68
- CERS $1.21
- Analyst Decision
- EOD
- CERS Strong Buy
- Analyst Count
- EOD 0
- CERS 2
- Target Price
- EOD N/A
- CERS $3.50
- AVG Volume (30 Days)
- EOD 118.1K
- CERS 1.2M
- Earning Date
- EOD 01-01-0001
- CERS 10-29-2025
- Dividend Yield
- EOD 9.28%
- CERS N/A
- EPS Growth
- EOD N/A
- CERS N/A
- EPS
- EOD N/A
- CERS N/A
- Revenue
- EOD N/A
- CERS $192,510,000.00
- Revenue This Year
- EOD N/A
- CERS $30.03
- Revenue Next Year
- EOD N/A
- CERS $9.37
- P/E Ratio
- EOD N/A
- CERS N/A
- Revenue Growth
- EOD N/A
- CERS 13.25
- 52 Week Low
- EOD $3.73
- CERS $1.12
- 52 Week High
- EOD $4.71
- CERS $2.24
- Technical
- Relative Strength Index (RSI)
- EOD 49.82
- CERS 43.44
- Support Level
- EOD $5.64
- CERS $1.17
- Resistance Level
- EOD $5.80
- CERS $1.35
- Average True Range (ATR)
- EOD 0.04
- CERS 0.07
- MACD
- EOD -0.00
- CERS -0.00
- Stochastic Oscillator
- EOD 21.88
- CERS 18.52
About EOD Allspring Global Dividend Opportunity Fund of Beneficial Interest
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.